ATR AptarGroup, Inc. - Fundamental Analysis
NEUTRAL
Sign in to save
Save this symbol to a watchlist or track a position.
ATR Stock | Fundamental Analysis & Investment Insights
NYSE
Healthcare
Medical Instruments & Supplies
Current Price
Live
$126.0
Analyst Target
$159.14
+26.3%
Upside
52W High
$164.28
52W Low
$103.23
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Jan 24, 2026
Market cap
$8.3B
P/E
19.97
ROE
15.6%
Profit margin
11.5%
Debt/Equity
0.46
Dividend yield
1.54%
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
78%
Analysis Accuracy
AptarGroup exhibits strong financial health with a Piotroski F-Score of 8/9, indicating robust fundamentals and consistent profitability. The company trades below its growth-based intrinsic value of $186.14 but at a premium to its Graham defensive value of $77.42, reflecting reasonable valuation given its earnings momentum. Despite solid ROE of 15.62% and low debt/equity of 0.46, insider selling and weak technical trend signal caution. Analysts recommend a 'buy' with a target price of $159.14, implying 26% upside, though recent price performance remains negative over the past year.
Key Strengths
Piotroski F-Score of 8 indicates exceptional financial strength and high-quality earnings
Strong profitability metrics: ROE of 15.62%, operating margin of 15.15%, and gross margin of 38.11%
Low leverage with Debt/Equity ratio of 0.46, well below sector average of 2.33
Earnings growth of 29.7% YoY and consistent EPS beats over the last 4 quarters (3 out of 4)
Dividend payout ratio of 28.89% is sustainable with room for future increases
Key Risks
Insider selling activity: $2.32M in sales over last 6 months with no buys, signaling bearish sentiment
Technical trend score of 0/100 indicates strong bearish momentum in price action
Current ratio of 1.19 and quick ratio of 0.72 suggest potential near-term liquidity pressure
Price down 20.1% over the past year despite strong earnings, indicating possible market skepticism
Missing Altman Z-Score prevents full assessment of bankruptcy risk; absence is a data red flag
AI Fair Value Estimate
Based on comprehensive analysis
$165.0
+31.0% above current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
73
Strong
68
75
80
85
55
AI Verdict
Moderately positive with caution due to technical and insider signals
Key drivers: High Piotroski score and strong ROE, Consistent earnings growth and beat rate, Low debt and solid margins, Bearish insider activity, Weak technical trend
Confidence
80%
Value
68/100
Ref P/E, PEG, Graham Number
Positives
- Trading below intrinsic value of $186.14
- P/E of 19.97 is reasonable vs forward earnings growth
Watchpoints
- Stock trades at premium to Graham Number ($77.42)
- Forward P/E of 22.51 implies high growth expectations
Future
75/100
Ref Growth rates
Positives
- 29.7% YoY earnings growth
- 27.9% Q/Q earnings growth
- Revenue growth of 5.7% YoY
Watchpoints
- Most recent Q/Q EPS growth was -2.4%, indicating a recent deceleration
Past
80/100
Ref Historical trends
Positives
- 17 out of last 25 quarters beat EPS estimates
- Average surprise of 3.88% over last 4 quarters
- Long-term consistency in profitability
Watchpoints
- 5Y price change of -3.9% underperforms sector growth trends
Health
85/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Piotroski F-Score of 8/9 indicates strong financial health
- Debt/Equity of 0.46 is conservative
- ROA of 6.84% is solid for sector
Watchpoints
- Quick ratio of 0.72 indicates limited liquid assets to cover short-term liabilities
- Altman Z-Score missing, limiting full solvency assessment
Dividend
55/100
Ref Yield, Payout
Positives
- Payout ratio of 28.89% is sustainable
- Dividend yield of 1.54% provides modest income
Watchpoints
- Dividend Strength score of 25/100 indicates weak historical dividend growth or consistency
- No 5-year average yield data available
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$126.0
Analyst Target
$159.14
Upside/Downside
+26.3%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ATR and closest competitors.
Updated 2026-01-23
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ATR
AptarGroup, Inc.
Primary
|
-3.9% | +15.9% | -20.1% | -21.4% | +2.6% | +1.0% |
|
AVTR
Avantor, Inc.
Peer
|
-61.5% | -48.8% | -46.0% | -17.0% | +4.6% | -3.0% |
|
BIO
Bio-Rad Laboratories, Inc.
Peer
|
-49.6% | -35.1% | -15.9% | +12.3% | -1.7% | -5.4% |
|
ARWR
Arrowhead Pharmaceuticals, Inc.
Peer
|
-23.4% | +107.3% | +265.3% | +85.2% | -10.6% | -8.0% |
|
BRKR
Bruker Corporation
Peer
|
-14.9% | -28.5% | -13.1% | +20.3% | +4.6% | +4.0% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
19.97
Forward P/E
22.5
PEG Ratio
N/A
P/B Ratio
2.98
P/S Ratio
2.27
EV/Revenue
2.55
EV/EBITDA
11.51
Market Cap
$8.3B
Profitability
Profit margins and return metrics
Profit Margin
11.45%
Operating Margin
15.15%
Gross Margin
38.11%
ROE
15.62%
ROA
6.84%
Growth
Revenue and earnings growth rates
Revenue Growth
+5.7%
Earnings Growth
+29.7%
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
+27.9%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.46
Low debt
Current Ratio
1.19
Good
Quick Ratio
0.72
Poor
Cash/Share
$4.04
Quarterly Earnings History
EPS performance vs analyst estimates
2026-02-05
$N/A
2025-10-30
$1.62
+3.1% surprise
2025-07-31
$1.66
+4.7% surprise
2025-05-01
$1.2
+3.9% surprise
Healthcare Sector Comparison
Comparing ATR against 147 companies in the Healthcare sector
(10 bullish, 55 neutral, 82 bearish)
P/E Ratio
19.97
This Stock
vs
164.56
Sector Avg
-87.9%
(Discount)
Return on Equity (ROE)
15.62%
This Stock
vs
-52.77%
Sector Avg
-129.6%
(Below Avg)
Profit Margin
11.45%
This Stock
vs
-20.78%
Sector Avg
-155.1%
(Weaker)
Debt to Equity
0.46
This Stock
vs
6.16
Sector Avg
-92.6%
(Less Debt)
Revenue Growth
5.7%
This Stock
vs
137.39%
Sector Avg
-95.9%
(Slower)
Current Ratio
1.19
This Stock
vs
3.36
Sector Avg
-64.6%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ATR
AptarGroup, Inc.
|
NEUTRAL | $8.3B | 19.97 | 15.6% | 11.5% | $126.0 | |
|
AVTR
Avantor, Inc.
|
BEARISH | $8.05B | - | -1.5% | -1.2% | $11.8 | |
|
BIO
Bio-Rad Laboratories, Inc.
|
NEUTRAL | $8.0B | - | -9.5% | -26.4% | $296.57 | |
|
ARWR
Arrowhead Pharmaceuticals, Inc.
|
BULLISH | $7.71B | 34.41 | 75.5% | 18.5% | $55.05 | |
|
BRKR
Bruker Corporation
|
BEARISH | $7.65B | - | -1.1% | -0.6% | $50.33 |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2025-12-12 | ACKERMAN DANIEL | Officer | Option Exercise | 15,000 | $1,066,800 |
| 2025-12-12 | ACKERMAN DANIEL | Officer | Sale | 15,000 | $1,818,435 |
| 2025-09-11 | TOUYA GAEL | Officer | Sale | 2,500 | $340,298 |
| 2025-09-05 | VINCZELLER SHIELA PALLERNE | Officer | Sale | 1,167 | $161,006 |
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
7 analysts
Wells Fargo
2026-01-06
Overweight
Equal-Weight
Wells Fargo
2025-11-03
Overweight
Overweight
Baird
2025-11-03
Outperform
Outperform
Wells Fargo
2025-09-10
Overweight
Overweight
Keybanc
2025-09-04
Overweight
Wells Fargo
2025-08-04
Overweight
Overweight
Raymond James
2025-08-04
Outperform
Outperform
Past News Coverage
Recent headlines mentioning ATR from our newsroom.
Newest → oldest
No matching news yet.